Literature DB >> 20164773

Cardiovascular disease in rheumatoid arthritis: a step forward.

Elena Myasoedova1, Sherine E Gabriel.   

Abstract

PURPOSE OF REVIEW: The present review highlights the recent findings on cardiovascular disease in rheumatoid arthritis (RA), and outlines the current concepts and prospects of cardiovascular disease detection and management in RA. RECENT
FINDINGS: Over the past year the knowledge of cardiovascular disease in RA has been augmented by a number of studies further explicating the interplay between RA and cardiovascular risk factors and highlighting the impact of inflammatory measures, immune mediators and other markers as early determinants of cardiovascular disease in RA. Other studies reported potential beneficial effects on cardiovascular outcomes for some antirheumatic medications.
SUMMARY: Knowledge of the increased burden of cardiovascular disease in RA is substantial and is continuously growing. Early detection, control and management of cardiovascular disease in RA appear to be a rapidly advancing field of research. However, much more work is needed to develop effective interventions to reduce cardiovascular morbidity and mortality in RA patients. More studies are needed to identify specific biomarkers for cardiovascular disease in RA and to develop cardiovascular risk scoring tools and evidence-based algorithms to promote more effective cardiovascular prevention and management of cardiovascular disease in RA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164773     DOI: 10.1097/BOR.0b013e3283379b91

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  8 in total

1.  Leptin as an obesity marker in rheumatoid arthritis.

Authors:  Maria Fernanda Brandão de Resende Guimarães; Marcus Vinícius Melo de Andrade; Carla Jorge Machado; Érica Leandro Marciano Vieira; Maria Raquel da Costa Pinto; Antônio Lúcio Teixeira Júnior; Adriana Maria Kakehasi
Journal:  Rheumatol Int       Date:  2018-06-11       Impact factor: 2.631

2.  Cardiovascular risk assessment in patients with rheumatoid arthritis: a correlative study of noninvasive arterial health testing.

Authors:  Erin M Scanlon; Rekha Mankad; Cynthia S Crowson; Iftikhar J Kullo; Sharon L Mulvagh; Eric L Matteson; Zoran Kvrgic; John M Davis
Journal:  Clin Rheumatol       Date:  2016-12-17       Impact factor: 2.980

Review 3.  Cardiovascular comorbidity in rheumatic diseases.

Authors:  Michael T Nurmohamed; Maaike Heslinga; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

4.  Cardiovascular disease in rheumatoid arthritis: a systematic literature review in latin america.

Authors:  Juan Camilo Sarmiento-Monroy; Jenny Amaya-Amaya; Juan Sebastián Espinosa-Serna; Catalina Herrera-Díaz; Juan-Manuel Anaya; Adriana Rojas-Villarraga
Journal:  Arthritis       Date:  2012-10-31

5.  Association of Cardiovascular Risk Factors with Carotid Intima Media Thickness in Patients with Rheumatoid Arthritis with Low Disease Activity Compared to Controls: A Cross-Sectional Study.

Authors:  Deborah F van Breukelen-van der Stoep; Derkjen van Zeben; Boudewijn Klop; Gert-Jan M van de Geijn; Hans J W Janssen; Mieke J M W Hazes; Erwin Birnie; Noelle van der Meulen; Marijke A De Vries; Manuel Castro Cabezas
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

6.  Trajectories of Fear-Avoidance Beliefs on Physical Activity Over Two Years in People With Rheumatoid Arthritis.

Authors:  Ingrid Demmelmaier; Annika Björk; Alyssa B Dufour; Birgitta Nordgren; Christina H Opava
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-03-25       Impact factor: 4.794

Review 7.  Does propolis have any effect on rheumatoid arthritis? A review study.

Authors:  Elyas Nattagh-Eshtivani; Naseh Pahlavani; Golnaz Ranjbar; Jamshid Gholizadeh Navashenaq; Ammar Salehi-Sahlabadi; Trias Mahmudiono; Mohammed Nader Shalaby; Mohammadhassan Jokar; Mohsen Nematy; Hanieh Barghchi; Shahrzad Havakhah; Mona Maddahi; Mohammad Rashidmayvan; Maryam Khosravi
Journal:  Food Sci Nutr       Date:  2022-03-10       Impact factor: 2.863

8.  Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.

Authors:  Victor M Rivera; Douglas R Jeffery; Bianca Weinstock-Guttman; Daena Bock; Fernando Dangond
Journal:  BMC Neurol       Date:  2013-07-11       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.